A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetic Profile and Pharmacodynamics of Single and Repeat Inhaled Doses of GSK961081 in Healthy Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- General safety and tolerability (adverse events, clinical laboratory safety tests, cardiac monitoring, vital signs (including postural changes in blood pressure), 12-lead ECG parameters including QTc(b) and QTc(f), blood glucose and serum potassium).
研究概览
简要总结
GSK961081 is a new long-acting bronchodilator being developed for the treatment of chronic obstructive pulmonary disease (COPD). This study is the first clinical study in humans. The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK961081 in healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy adult males aged between 18 and 50 years.
- •Body mass index within the range 18.5-29.9 kilograms/meter2 (kg/m2).
- •Forced Expiratory Volume in 1 second (FEV1) <80% predicted and a FEV1/ Forced Vital Capacity (FVC) ratio <0.7
- •Response to Salbutamol defined as: an increase in sGAW of >15% over pre-dose baseline within 2 h following administration of 400 mcg Salbutamol by MDI inhaler OR: a documented increase in sGAW of >15% over pre-dose baseline within 2 h following administration of 400 mcg Salbutamol by MDI inhaler within 6 months of screening.
- •Response to Ipratropium bromide defined as: an increase in sGaw of >25% over pre-dose baseline within 2 h following 80 mcg Ipratropium bromide; OR: a documented increase in sGaw of >25% over pre-dose baseline 2 h following administration of 80 mcg Ipratropium bromide within 6 months of screening.
- •A signed and dated written informed consent is obtained for the subject
- •The subject is able to understand and comply with the protocol requirements, instructions and protocol-stated restrictions.
- •Subjects who are current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of > or = 10 pack years.
- •[number of pack years = (number of cigarettes per day/20) x number of years smoked]
排除标准
- •Any clinically relevant abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or ECG (12-lead or Holter).
- •A history of breathing problems (i.e. history of asthmatic symptoms). Screening lung function tests (FEV1, FVC and sGaw) will be performed to confirm normal lung function parameters.
- •A mean QTc(B) and QTc(F) value at screening >430msec, the 3 screening ECGs are not within 10% of the mean, a PR interval outside the range 120-210msec or an ECG that is not suitable for QT measurements (e.g. poorly defined termination of the T wave).
- •A supine blood pressure that is persistently higher than 140/90 millimetres of mercury (mmHg) at screening.
- •A supine mean heart rate outside the range 40-90 beats per minute (bpm) at screening.
- •The subject has donated a unit of blood within the 90 days or intends to donate within 90 days after completing the study.
- •A history of claustrophobia such that they may not tolerate plethysmography measurements.
- •The subject is currently taking regular (or course of) medication whether prescribed or not, including vitamins and herbal remedies such as St John's Wort.
- •The subject has used prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (which ever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety.
- •The subject has participated in a clinical study with another New Chemical Entity (NCE) within the past 112 days or a clinical study with any other drug during the previous 84 days.
- •The subject is infected with the Hepatitis B, Hepatitis C, or HIV virus.
- •The subject has a positive pre-study urine cotinine/ breath carbon monoxide test, urine drug/urine alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbituates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.
- •A history of regular alcohol consumption exceeding weekly intake of alcohol greater than 28 units, or an average daily intake of greater than 4 units.
- •Are unable to use the Prodose AAD nebuliser device correctly.
- •An unwillingness of subjects to abstain from sexual intercourse with pregnant or lactating women; or an unwillingness of the subject to use a condom/spermicide in addition to having their female partner use another form of contraception such as IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or tubal ligation if the woman could become pregnant from the time of the first dose study medication until 90 days post-dose.
- •The subject has a history of drug or other allergy, which, in the opinion of the responsible physician, contraindicates their participation.
- •The subject has a history of hypersensitivity to Salbutamol or Ipratropium bromide, and for those subjects in cohorts III and IV, hypersensitivity to a beta-blocker.
- •The subject has had a lower respiratory tract infection within 4 weeks of study start
研究组 & 干预措施
Cohort 1, period 1
Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
干预措施: Placebo SD (Drug)
Cohort 1, Period 2
GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
干预措施: GSK961081 15mcg SD (Drug)
Cohort 1, Period 2
GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
干预措施: GSK961081 3mcg SD (Drug)
Cohort 1, Period 2
GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
干预措施: GSK961081 50mcg SD (Drug)
Cohort 1, Period 2
GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
干预措施: Placebo SD (Drug)
Cohort 1, period 1
Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
干预措施: GSK961081 15mcg SD (Drug)
Cohort 1, period 1
Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
干预措施: GSK961081 3mcg SD (Drug)
Cohort 1, period 1
Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
干预措施: GSK961081 50mcg SD (Drug)
Cohort 1, period 3
GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
干预措施: GSK961081 15mcg SD (Drug)
Cohort 1, period 3
GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
干预措施: GSK961081 3mcg SD (Drug)
Cohort 1, period 3
GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
干预措施: GSK961081 50mcg SD (Drug)
Cohort 1, period 3
GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
干预措施: Placebo SD (Drug)
Cohort 1, period 4
GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
干预措施: GSK961081 15mcg SD (Drug)
Cohort 1, period 4
GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
干预措施: GSK961081 3mcg SD (Drug)
Cohort 1, period 4
GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
干预措施: GSK961081 50mcg SD (Drug)
Cohort 1, period 4
GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
干预措施: Placebo SD (Drug)
Cohort 2, period 1
Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
干预措施: Placebo SD (Drug)
Cohort 2, period 1
Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
干预措施: GSK961081 100mcg SD (Drug)
Cohort 2, period 1
Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
干预措施: GSK961081 200mcg SD (Drug)
Cohort 2, period 1
Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
干预措施: GSK961081 300mcg SD (Drug)
Cohort 2, period 2
GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
干预措施: Placebo SD (Drug)
Cohort 2, period 2
GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
干预措施: GSK961081 100mcg SD (Drug)
Cohort 2, period 2
GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
干预措施: GSK961081 200mcg SD (Drug)
Cohort 2, period 2
GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
干预措施: GSK961081 300mcg SD (Drug)
Cohort 2, period 3
GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
干预措施: Placebo SD (Drug)
Cohort 2, period 3
GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
干预措施: GSK961081 100mcg SD (Drug)
Cohort 2, period 3
GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
干预措施: GSK961081 200mcg SD (Drug)
Cohort 2, period 3
GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
干预措施: GSK961081 300mcg SD (Drug)
Cohort 2, period 4
GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
干预措施: Placebo SD (Drug)
Cohort 2, period 4
GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
干预措施: GSK961081 100mcg SD (Drug)
Cohort 2, period 4
GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
干预措施: GSK961081 200mcg SD (Drug)
Cohort 2, period 4
GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
干预措施: GSK961081 300mcg SD (Drug)
Cohort 3
GSK961081 100mcg or Placebo
干预措施: GSK961081 100mcg RD (Drug)
Cohort 3
GSK961081 100mcg or Placebo
干预措施: Placebo RD (Drug)
Cohort 4
GSK961081 300mcg or Placebo
干预措施: GSK961081 300mcg RD (Drug)
Cohort 4
GSK961081 300mcg or Placebo
干预措施: Placebo RD (Drug)
结局指标
主要结局
General safety and tolerability (adverse events, clinical laboratory safety tests, cardiac monitoring, vital signs (including postural changes in blood pressure), 12-lead ECG parameters including QTc(b) and QTc(f), blood glucose and serum potassium).
时间窗: Pre and post-dose on Days 1, 4 and 7
次要结局
- Maxiumum and weighted mean (over 0-8 hours post-dose) for systolic and diastolic blood pressure, heart rate, QTc(F), QTc(B), plasma glucose and serum potassium(Days 1, 4 and 7)
- specific airway conductance (sGaW)(pre and post-dose on Days 1, 4 and 7)
- forced expiratory volume in one second (FEV1)(Pre and post-dose on Days 1, 4 and 7)